Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is indicated for several clinical situations where fibrinogen replacement is required.

• Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) to prevent or treat bleeding episodes.
• Acquired hypofibrinogenemia associated with liver disease, massive transfusion, or disseminated intravascular coagulation.
• Massive hemorrhage during surgery or trauma when rapid fibrinogen supplementation is needed.
• Cardiopulmonary bypass or extracorporeal membrane oxygenation procedures where fibrinogen levels may fall.
• Obstetric hemorrhage, such as postpartum bleeding, when fibrinogen levels are low.
• Bleeding complications in patients with inherited coagulation disorders who have secondary fibrinogen depletion.

The safety profile of Haemocomplettan P reflects the typical reactions observed with plasma‑derived fibrinogen products.

Common

• Mild fever or chills during or after infusion.
• Transient headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Local infusion site reactions such as erythema or mild swelling.
• Transient hypotension or mild tachycardia during infusion.
• Mild fatigue or feeling of weakness after administration.

Serious

• Allergic reactions including urticaria, bronchospasm, or anaphylaxis.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Volume overload, particularly in patients with cardiac failure.
• Disseminated intravascular coagulation exacerbation.
• Renal impairment or acute kidney injury in susceptible individuals.
• Severe bleeding due to uncontrolled coagulopathy unrelated to fibrinogen deficiency.

When prescribing Haemocomplettan P, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline fibrinogen level and overall coagulation status before administration.
• Use caution in patients with a history of thromboembolic disease or active clot formation.
• Monitor for signs of allergic reaction during and after infusion, especially in individuals with prior plasma product sensitivities.
• Evaluate cardiac function and fluid status to avoid volume overload in patients with heart failure.
• Avoid use in patients with uncontrolled disseminated intravascular coagulation until the underlying condition is managed.
• Consider renal function; adjust dosing or monitoring in severe renal impairment.

Haemocomplettan P may interact with other agents that affect coagulation or hemodynamics.

Avoid

• Concomitant use of pro‑coagulant agents (e.g., activated factor VII) that could increase thrombotic risk.
• High‑dose anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors) administered immediately before fibrinogen infusion without appropriate monitoring.
• Concurrent administration of fibrinolytic agents (e.g., alteplase) may counteract the hemostatic effect of fibrinogen replacement.

Use with caution

• Antifibrinolytic drugs (e.g., tranexamic acid) as combined therapy may enhance clot stability.
• Other plasma‑derived products (e.g., cryoprecipitate, factor concentrates) to prevent excessive fibrinogen levels.
• Medications that cause fluid retention or affect cardiac output (e.g., certain antihypertensives) in patients at risk of volume overload.